Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects

Ertugliflozin, a sodium‐glucose cotransporter 2 inhibitor, is approved for treatment of type 2 diabetes. This randomized, double‐blind (sponsor‐open) study in healthy Japanese subjects and open‐label study in Western subjects assessed ertugliflozin pharmacokinetics and pharmacodynamics. Cohort A rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yinhua, Nucci, Gianluca, Yamamoto, Yuichi, Fediuk, Daryl J., Sahasrabudhe, Vaishali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359436/
https://www.ncbi.nlm.nih.gov/pubmed/33434408
http://dx.doi.org/10.1002/cpdd.908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359436/
https://www.ncbi.nlm.nih.gov/pubmed/33434408
http://dx.doi.org/10.1002/cpdd.908

Ejemplares similares